Search research articles
Contact Us
Filters
Showing results (41-50 of 222) with videos related to
Page
of 23
Sort By:
Clinical Advances in Hematology & Oncology : H&O
|
February 25, 2012
Recent advances and updated guidelines in the management of chemotherapy-induced nausea and vomiting
Lee S Schwartzberg, Steven M Grunberg, Mark G Kris
Surgical Endoscopy
|
December 31, 1997
First trimester of pregnancy laparoscopic procedures
B S Schwartzberg, J A Conyers, J A Moore
The Journal of Supportive Oncology
|
November 4, 2006
A prospective investigation of chemotherapy-induced neutropenia and quality of life
Barry V Fortner, Arthur C Houts, Lee S Schwartzberg
Future Oncology (London, England)
|
November 19, 2020
Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer
Karen E Skinner, Amin Haiderali, Min Huang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 10, 2017
Selective Androgen Receptor Modulator in a Patient With Hormone-Positive Metastatic Breast Cancer
Namratha Vontela, Vamsi Koduri, Lee S Schwartzberg, et al.
Journal of Comparative Effectiveness Research
|
November 10, 2020
Assessing direct costs of treating metastatic triple-negative breast cancer in the USA
Karen E Skinner, Amin Haiderali, Min Huang, et al.
Critical Reviews in Oncology/Hematology
|
February 11, 2012
The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies
Lee S Schwartzberg, Peter Jacobs, Panagiota Matsouka, et al.
Cancer Treatment and Research
|
January 1, 1995
High-dose chemotherapy and autologous stem cell transplantation for breast cancer
C H Weaver, R Birch, L S Schwartzberg, et al.
The Breast Journal
|
September 19, 2019
Real-world effectiveness of fulvestrant monotherapy as first endocrine treatment in patients with metastatic breast cancer
Karen E Skinner, Temitope Olufade, Mark S Walker, et al.
Clinical Breast Cancer
|
February 26, 2014
Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer
Lee S Schwartzberg, Suprith Badarinath, Mark R Keaton, et al.
Page
of 23
Search research articles
Search
Showing results (41-50 of 222) with videos related to
Sort By:
Page
of 23
Clinical Advances in Hematology & Oncology : H&O
|
February 25, 2012
Recent advances and updated guidelines in the management of chemotherapy-induced nausea and vomiting
Lee S Schwartzberg, Steven M Grunberg, Mark G Kris
Surgical Endoscopy
|
December 31, 1997
First trimester of pregnancy laparoscopic procedures
B S Schwartzberg, J A Conyers, J A Moore
The Journal of Supportive Oncology
|
November 4, 2006
A prospective investigation of chemotherapy-induced neutropenia and quality of life
Barry V Fortner, Arthur C Houts, Lee S Schwartzberg
Future Oncology (London, England)
|
November 19, 2020
Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer
Karen E Skinner, Amin Haiderali, Min Huang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 10, 2017
Selective Androgen Receptor Modulator in a Patient With Hormone-Positive Metastatic Breast Cancer
Namratha Vontela, Vamsi Koduri, Lee S Schwartzberg, et al.
Journal of Comparative Effectiveness Research
|
November 10, 2020
Assessing direct costs of treating metastatic triple-negative breast cancer in the USA
Karen E Skinner, Amin Haiderali, Min Huang, et al.
Critical Reviews in Oncology/Hematology
|
February 11, 2012
The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies
Lee S Schwartzberg, Peter Jacobs, Panagiota Matsouka, et al.
Cancer Treatment and Research
|
January 1, 1995
High-dose chemotherapy and autologous stem cell transplantation for breast cancer
C H Weaver, R Birch, L S Schwartzberg, et al.
The Breast Journal
|
September 19, 2019
Real-world effectiveness of fulvestrant monotherapy as first endocrine treatment in patients with metastatic breast cancer
Karen E Skinner, Temitope Olufade, Mark S Walker, et al.
Clinical Breast Cancer
|
February 26, 2014
Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer
Lee S Schwartzberg, Suprith Badarinath, Mark R Keaton, et al.
Page
of 23